Board of Directors
Aditya PolsaniDirector, Business Development for Academic Drug Discovery Consortium, Johns Hopkins University
Aditya Polsani is the co-founder of Academic Drug Discovery Consortium (ADDC) and Director of Business Development at Johns Hopkins University�s Brain Science Institute and Biomedical Engineering department. He manages sales, marketing, fund raising, and business development activities at ADDC.
Aditya was Industrial Liaison Associate for the Biomedical Engineering department and the Brain Science Institute at Johns Hopkins University from 2005 - 2011. He managed technology incubation, development and commercialization activities in Biomedical Engineering department and Brain Science Institute, facilitated sponsored research activities, built strategic research partnerships with medical device, biotech & pharma companies like JNJ, Eisai, Biogen, and raised money from industry and non-profit entities for research programs. He also managed a portfolio of over 125 invention disclosures covering wide array of departments (biomedical engineering, neurology, cardiology, ophthalmology, orthopedic surgery, radiology) and executed multiple licensing agreements with startups and established pharma and medical device companies.
He co-founded the Center for Bioengineering Innovation & Design (CBID) program in biomedical engineering department in 2007, developed and implemented strategic vision of the center, designed and established the Technology Accelerator Fund (TAF) with seed funding from Johnson and Johnson. At CBID, he was also involved with recruiting and building biomedical design teams comprising of students, clinicians and engineers, sourcing medical device projects and managing intellectual property.
While pursuing his master's degree at Johns Hopkins, Aditya co-founded and became the first president of Hopkins Biotech Network (HBN). As the co-founder/president, he built HBN from 6 members to a 1200 member organization in a span of fifteen months. He led a team comprised of three vice-presidents and four directors spanning three Hopkins campuses, and raised money from various entities within Hopkins and the biotech industry to support HBN programs. Organization members comprised of a diverse group of people including scientists, students, clinicians, venture capitalists, entrepreneurs, consultants and business development executives from biotech & pharma industry.
Barbara SlusherDirector, Johns Hopkins Drug Discovery
Dr. Slusher is the Director of Johns Hopkins Drug Discovery at Johns Hopkins School of Medicine. She leads a 20-member veteran drug-discovery team consisting of medicinal chemists, assay developers, pharmacologists, toxicologists, and pharmacokinetic/drug metabolism experts. The team is engaged in identifying novel drug targets arising from JHU faculty's research and translating them into new drug therapies for neurological disorders.
Prior to joining Hopkins in September 2009, she spent 18 years in the pharmaceutical industry, including several years as a Senior Vice President of Research and Translational Development. Dr. Slusher's extensive experience in drug discovery spans through Phase I/IIa clinical development, participation in multiple FDA meetings and both IND and NDA regulatory filings. She is an inventor of over fifty issued patents and applications and has published over 120 scientific articles, reviews and book chapters. She has been an invited speaker at many national and international scientific meetings and has served on the Board or as a scientific consultant of multiple biotechnology companies.
Dr. Slusher received her undergraduate degree from Dickinson College where she graduated valedictorian, majoring in Chemistry. She received her Ph.D. in Pharmacology and Molecular Sciences from John Hopkins School of Medicine while simultaneously earning her Master's degree in Administrative Science from Johns Hopkins School of Continuing Studies.
P. Jeffrey Conn, PhDVanderbilt Center for Neuroscience Drug Discovery
Dr. Conn is the Lee E. Limbird Professor of Pharmacology at Vanderbilt University and Director of the Vanderbilt Center for Neuroscience Drug Discovery. Dr. Conn received the Ph.D. degree in Pharmacology from Vanderbilt in 1986 and pursued postdoctoral studies at Yale University. Dr. Conn joined the faculty of the Department of Pharmacology at Emory University in 1988 where he where he established himself as a leader in studies of neurotransmitter receptors and their roles in regulating brain function in circuits involved in psychiatric and neurological disorders. In 2000, Dr. Conn assumed the position of Senior Director and Head of the Department of Neuroscience at Merck and Company in West Point, PA. Dr. Conn moved to Vanderbilt University in 2003 as the founding director of the Vanderbilt Program in Drug Discovery (VPDD), with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. By 2011 the VPDD had grown to approximately 100 full time scientists and raised over $80M in research funding. In addition, the VPDD advanced novel molecules from three major programs into development for clinical testing in major brain disorders with industry partners. A fourth program reached development status and is advancing internally at Vanderbilt. To mark this growth and facilitate more fluid integration of drug discovery, development, and corporate partnerships, the VPDD achieved independent center status and was named the Vanderbilt Center for Neuroscience Drug Discovery in January 2011. Dr. Conn is Editor in Chief of Molecular Pharmacology, Regional Editor (North America) of Current Neuropharmacology and serves on the editorial boards of 6 other international journals. He has served the Scientific Advisory Boards of multiple foundations and companies in the pharmaceutical and biotech industries. He currently serves as the founding director of the scientific advisory board of Karuna Pharmaceuticals and on the advisory boards of Seaside Therapeutics and the Michael J. Fox Foundation. He served as Chairman of the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET) and on multiple national and international committees. He has received numerous awards, including the NARSAD Essel Distinguished Investigator Award, the ASPET-Astellas Award in Translational Pharmacology, the Pharmacia - ASPET Award for Experimental Therapeutics, the Charles R. Park Award for Basic Research Revealing Insights into Physiology and Pathophysiology, the PhRMA Foundation Award for Excellence in Pharmacology and Toxicology. He was named as an ISI Most-Cited Scientists in Pharmacology & Toxicology and the Lee University 2008 Distinguished Alumnus of the Year. Dr. Conn's current research is focused on development of novel treatment strategies for schizophrenia, Parkinson's disease, and other serious brain disorders.
Michelle Arkin, PhDSmall Molecule Discovery Center, University of California, San Francisco
Michelle Arkin is the Associate Director of Biology at the Small Molecule Discovery Center and Associate Adjunct Professor in the Department of Pharmaceutical Chemistry at UCSF. She directs the high-throughput screening facility at the SMDC and engages in grant-funded small-molecule discovery research. Dr. Arkin's research interests are in developing innovative approaches to tackle challenging targets (such as protein-protein interfaces and allosteric enzymes) and orphan/neglected diseases (including infectious and neurodegenerative diseases). She is co-PI for the Fragment Discovery Center of the Chemical Biology Consortium at the NCI. Dr. Arkin received her PhD in chemistry at Caltech and then held a Daymon Runyon Cancer Foundation postdoctoral fellowship at Genentech. She was among the first scientists at Sunesis Pharmaceuticals, where she helped to develop fragment-based approaches for inhibiting protein-protein interactions and biophysical tools to characterize protein/small-molecule interactions. Her teams developed the first nanomolar inhibitors of interleukin-2, and an LFA1 antagonist (SAR1118), currently completing phase 3 trials for dry-eye. From 2005 to 2007, she was the Associate Director of Cell Biology at Sunesis and led the translational science team for Vosaroxin, an anti-cancer agent in phase 3 clinical trials for acute myelogenous leukemia.
Marcie Glicksman, PhDChief Scientific Officer at ORIG3N
Dr. Glicksman is the Chief Scientific Officer at ORIG3N, a new start-up biotechnology company focused on building the largest biorepository of cells to understand the molecular and cellular foundations of disease. Dr Glicksman was the Co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN) which is part of the Harvard NeuroDiscovery Center and assistant professor in the Neurology Department at Brigham and Women's Hospital and Harvard Medical School. She received a bachelor's degree from Brown University and a Ph.D. in Neuroscience from Washington University. Dr. Glicksman has extensive experience in assay development, high throughput screening, and chemical databases, as well as animal pharmacology and preclinical development. She has been in the field of drug discovery for twenty years, the most recent six years in academics and more than ten years in the pharmaceutical /biotechindustry. Before joining LDDN, she was at the start-up company, Descartes Therapeutics. Before this, she was Director of Leads Discovery at Cubist leading a group in the development of antibiotics with a structure-based drug design approach using x-ray crystallography and chemical modeling, which resulted in lead molecules suitable for testing in animal models. Before Cubist, she was in Leads Discovery at DuPont-Merck (later DuPont Pharmaceuticals) and Cell Biology at Cephalon, Inc. She led the assay development and screening programs for many cell-based and biochemical assays including a protease project and numerous G-protein coupled receptor projects. She also has led a program for Alzheimer's and Parkinson's disease that resulted in co-inventorship of CEP1347, a drug candidate directed at a kinase in Phase III clinical trials. She was elected in 2005 to the Board of Directors for the non-profit drug discovery organization, the Society for Biomolecular Sciences and served as its Chairman for two years. She is on the science advisory board for the Alzheimer's disease foundation (ADDF/ISOA) and the California Institute for Regenerative Medicine (CIRM), and reviews grants for NIH and the Michael J Fox foundation. She also regularly consults and this has included filing an Investigational New Drug application with the FDA, as well as projects involving the development of new technologies.
Stephen V. Frye, PhDThe Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill
Stephen Frye is Professor and Director of the Center for Integrative Chemical Biology and Drug Discovery at UNC-Chapel Hill. His research focuses on oncology drug discovery and the chemical biology of chromatin regulation. Before joining UNC in 2007, he served as worldwide Vice President for High Throughput and Discovery Medicinal Chemistry at GlaxoSmithKline. During his 20 years at GSK, his creation and leadership of a department focused on oncology and protein kinases resulted in the discovery of several marketed drugs and he is also the inventor of Avodart, GlaxoSmithKline's drug approved for treatment of benign prostate disease.
Matthew HartmanJohns Hopkins Brain Science Institute
Matthew Hartman is Director, Business Development for the Brain Science Institute at Johns Hopkins, as well as a contract negotiator for the Johns Hopkins Technology Transfer Office. Matthew has been with Johns Hopkins for four and a half years, the last four of which were with Johns Hopkins Technology Transfer, negotiating with both academic and corporate partners. His experience in technology transfer, combined with his J.D. and M.B.A. from the University of Baltimore, allow him to effectively bridge the worlds of industry and academia. He is currently licensed to practice law in the state of Maryland. Matthew can be reached at firstname.lastname@example.org or by phone at 410-614-2075.
Cheryl Arrowsmith is a Senior Scientist at Princess Margaret Cancer Centre and Professor in the Department of Medical Biophysics at the University of Toronto, where she holds a Canada Research Chair in Structural Genomics. She received a Ph.D. in chemistry from the University of Toronto and carried out postdoctoral research at Stanford University in the area of protein NMR spectroscopy. Dr. Arrowsmith�s research focuses on the use of structural and chemical biology methods for understanding the structure-function relationships of proteins and their role in cancer. Dr. Arrowsmith is the Chief Scientist of the Toronto Node of the Structural Genomics Consortium (SGC), a European-Canadian public-private partnership that supports the discovery of new medicines through open access research.
- Board of Directors
- Management Team